A cost-effectiveness model of tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women in Sweden

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The results of the study suggested "the administration of tibolone to women with osteopenia and osteoporosis for the prevention of osteoporosis-related bone fractures is cost-effective in Sweden relative to a policy of no treatment, especially when treatment is initiated around the onset of menopause (around 53 years of age) and treatment is administered for a duration of 5 years".